A Prospective Multicentre Real-world Assessment of the Efficacy of Danning Tablets in Alleviating Digestive Symptoms

Launched by SHANGHAI HUTCHISON PHARMACEUTICALS LIMITED · Dec 24, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective Danning Tablets are in relieving digestive symptoms such as indigestion, bloating, upper abdominal pain, loss of appetite, acid reflux, and constipation. The researchers want to find out how well these tablets work for patients who are already using them as part of their regular treatment for these symptoms. They will ask participants to fill out questionnaires about their symptoms after two weeks and again after four weeks of taking the tablets.

To join this study, participants need to be between 18 and 75 years old and must be experiencing at least one of the digestive symptoms mentioned. It's important that they are already taking Danning Tablets as part of their treatment. However, certain individuals, such as those with a history of severe illnesses or recent surgeries, may not be eligible. The trial is not yet recruiting participants, but it aims to gather valuable information on how well Danning Tablets work and what factors may influence their effectiveness.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients between 18 and 75 years old
• • Patients with at least one of the following symptoms: upper abdominal pain, bloating, loss of appetite, acid reflux or constipation
• • Patients already taking Danning Tablets as part of their regular medicine treatment for dyspepsia
• • Patients agree to sign the informed consent form
• Exclusion Criteria:
• • Past history or comorbidity of malignant tumor
• • Comorbidity of severe systemic condition including cardiovascular, cerebrovascular, renal and hematopoietic system diseases
• • Past history of abdominal surgery (post pancreatic surgery, post subtotal gastrectomy; incomplete intestinal obstruction) or mental illness, mobility difficulty (e.g. long-term bed ridden)
• • Comorbidity of any unstable chronic or acute disease,which may impact the evaluation of treatment efficacy as determined by the research physician
• • Pregnancy or breastfeeding
• • Participation in other clinical trials within the past 3 months
• • Other circumstances determined as ineligible by the research physician